Cargando…

Correction: ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148082/ https://www.ncbi.nlm.nih.gov/pubmed/27936143 http://dx.doi.org/10.1371/journal.pone.0168221

Ejemplares similares

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Correction: ALK inhibitors in ALK-rearranged nonsmall cell lung cancer with and without brain metastases: systematic review and network meta-analysis
Publicado: (2022)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Correction: Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase
por: Zhu, Jiang, et al.
Publicado: (2022)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2023)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Correction: Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer
Publicado: (2020)

Correction: Cancer Mortality by Country of Birth, Sex, and Socioeconomic Position in Sweden, 1961–2009
Publicado: (2014)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Correction to: Pediatric Insulin Injection Technique: A Multi-Country Survey and Clinical Practice Implications
por: Kalra, Sanjay, et al.
Publicado: (2018)

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
por: Poh, Mau Ern, et al.
Publicado: (2023)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Patient-led advocacy in ALK-positive lung cancer
por: Barton, Colin, et al.
Publicado: (2023)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
por: Waterhouse, David M., et al.
Publicado: (2020)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Correction to “Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report”
Publicado: (2023)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
por: Chia, Puey Ling, et al.
Publicado: (2014)

Correction to: Optimization of pediatric CT scans in a developing country
por: Fotso Kamdem, Eddy, et al.
Publicado: (2021)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study
por: Lococo, Filippo, et al.
Publicado: (2023)

Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer
por: Yamasaki, Masahiro, et al.
Publicado: (2017)

Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers
por: Saifullah, et al.
Publicado: (2022)

Correction to: Lung ultrasound predicts clinical course and outcomes in COVID-19 patients
por: Lichter, Yael, et al.
Publicado: (2020)

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors
por: Berry, M. A., et al.
Publicado: (2023)

Correction: Addressing the Global Neglect of Childhood Hearing Impairment in Developing Countries
por: Olusanya, Bolajoko O
Publicado: (2007)

Correction: Gastroenteritis Therapies in Developed Countries: Systematic Review and Meta-Analysis
por: Freedman, Stephen B., et al.
Publicado: (2017)

Correction to: Review of global neurosurgery education: Horizon of Neurosurgery in the Developing Countries
por: Kato, Y., et al.
Publicado: (2020)

Correction: Use of Evidence-Based Practices in Pregnancy and Childbirth: South East Asia Optimising Reproductive and Child Health in Developing Countries Project
Publicado: (2008)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a0oo9hqg0k9gt0kgj60vgrooqt